Hospitalist Doctors in Fairlawn, OH Accepting Medicare

5 Hospitalist doctors found. Showing 1 - 5

Jennifer Jianfang Feng, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 822 Kumho Dr, Ste 202, Fairlawn, OH 44333 Phone: 330-576-0500    Fax: 330-576-0467

Michael H Linz, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 822 Kumho Dr Ste 202, Fairlawn, OH 44333 Phone: 330-576-0500    Fax: 330-576-0467

Anna Ayoub, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 822 Kumho Dr, Suite 202, Fairlawn, OH 44333 Phone: 330-576-0500    Fax: 330-576-0467

Dr. Latha M. Jayaraman, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 822 Kumho Dr, Suite Number 202, Fairlawn, OH 44333 Phone: 330-576-0500    Fax: 330-576-0467

Herve Leblanc, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 822 Kumho Dr, Fairlawn, OH 44333 Phone: 330-576-0500

News Archive

Eckert & Ziegler enters exclusive sales agreement with Zyklotron for Fluorodeoxyglucose

Eckert & Ziegler Strahlen- und Medizintechnik AG, a company specializing in special compounds for the diagnosis and treatment of cancer, via its subsidiary company Eckert & Ziegler f-con Deutschland GmbH closed an exclusive sales agreement with the Karlsruhe-based ZAG Zyklotron AG for the regular delivery of Fluorodeoxyglucose (18F) (FDG). FDG is used in the context of the so called Positron Emission Tomography (PET) for the safe and quick recognition of even the smallest tumour foci.

Emerson Ecologics to exclusively distribute Sedona Labs Pro probiotic products

Emerson Ecologics, LLC, the leading provider of professional-grade nutritional supplements to the healthcare practitioner market, announces a new strategic partnership with Nutri-Health as the exclusive distributor for their practitioner brand, Sedona Labs Pro™. Effective immediately, all customer service, marketing and order fulfillment for the complete line of Sedona Labs Pro products will be handled by Emerson Ecologics.

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

Scientists complete protein 3D structural sequence essential for cellular function

Researchers at IRB Barcelona have completed the 3D structural sequence adopted by several essential proteins in the exchange of substances between the extra and intracellular milieu. This finding provides a global perspective of the structural changes that occur in these relevant proteins during basic cell processes, such as protein synthesis, the regulation of metabolism and cell volume, and nerve transmission.

ITDS can be effective for screening fever during H1N1 influenza pandemic: UNMC researchers

Researchers at the University of Nebraska Medical Center found an Infrared Thermal Detection System to be a fast and effective fever screening tool in clinical settings during the H1N1 influenza pandemic. The ITDS detected fever in patients through split-second, non-contact skin temperature measurements.

Read more Medical News

› Verified 2 days ago